KASL clinical practice guidelines for management of chronic hepatitis B
Clin Mol Hepatol. 2019;25(2):93-159.   Published online 2019 Jun 12     DOI: https://doi.org/10.3350/cmh.2019.1002
Citations to this article as recorded by Crossref logo
Reply to: “Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: One direction or no direction”
Beom Kyung Kim
Journal of Hepatology.2019; 71(4): 847.     CrossRef
Validation of the CAMD Score in Patients With Chronic Hepatitis B Virus Infection Receiving Antiviral Therapy
Seung Up Kim, Yeon Seok Seo, Han Ah Lee, Mi Na Kim, Eun Hwa Kim, Ha Yan Kim, Yu Rim Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seong Gyu Hwang, Kyu Sung Rim, Soon Ho Um, Won Young Tak, Young Oh Kweon, Beom Kyung Kim, Soo
Clinical Gastroenterology and Hepatology.2019;[Epub]     CrossRef
Reply to: “Comment on – A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in the Republic of Korea”
Beom Kyung Kim
Journal of Hepatology.2019;[Epub]     CrossRef
New Potential Therapies for Chronic Hepatitis B
Sun Hong Yoo, Jung Hyun Kwon
The Korean Journal of Gastroenterology.2019; 74(5): 267.     CrossRef
Long Term Efficacy of Antiviral Therapy: Mortality and Incidence of Hepatocellular Carcinoma
Hyun Woong Lee
The Korean Journal of Gastroenterology.2019; 74(5): 251.     CrossRef
Prophylactic Antiviral Treatment in Immunosuppressed Chronic Hepatitis B Patients
Eileen L. Yoon
The Korean Journal of Gastroenterology.2019; 74(5): 258.     CrossRef
Natural History and Treatment Indications of Chronic Hepatitis B
Dong Hyun Sinn
The Korean Journal of Gastroenterology.2019; 74(5): 245.     CrossRef